Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide + Epirubicin in First-line Advanced Leiomyosarcoma
NCT05204524Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in leiomyosarcoma (LMS), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
temozolomide
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT05204524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204524.